DESCRIPTION (from Applicant's Abstract): Both lipids and proteins are
sites of ethanol action. There have been an extensive number of studies
on effects of ethanol on lipid structure. However, while quite a few
studies examined effects of ethanol on protein function, there is little
information known on how ethanol actually alters protein activity. It
has been previously proposed that ethanol directly binds to proteins,
but that conclusion has been largely based on effects of ethanol o
protein function. Another issue is if ethanol directly binds to a
protein what are the consequences of that binding on protein function.
Preliminary data indicate that ethanol indeed directly binds to certain
lipid transfer proteins, i.e., sterol carrier binding protein-2 (SCP-2),
liver-fatty acid binding protein (L-FABP) and bovine serum albumin
(BSA). In addition, we observed that ethanol displaced cis-parinaric
acid from some, but not all fatty acid-binding sites on BSA. Thus, not
only does ethanol directly bind to some proteins but it selectively
binds to certain hydrophobic sites. It is the overall hypothesis of
this new application that ethanol directly binds to hydrophobic areas of
SCP-2 and L-FABP, two proteins that are affected by chronic ethanol
consumption. We further proposed that ethanol inhibits the binding of
endogenous ligands to SCP-2 and L-FABP and modifies sterol transport
between membranes. These hypotheses will be examined using the powerful
combination of fluorescence spectroscopy and 13C NMR relaxation
technique. The specific aims of this application are: 1)
characteristics of cholesterol phospholipids and fatty acids binding to
SCP-2 and L-FABP will be examined in the absence and presence of ethanol
in vitro using fluorescence techniques; 2) the binding geometry of
ethanol and fatty acids to SCP-2 and L-FABP will be studied using 13C-
ethanol NMR relaxation data; and 3) effects of SCP-2 and L-FABP enhanced
sterol exchange between liver membranes will be evaluated. Chronic
alcohol abuse is the most important cause of morbidity and mortality
from liver disease in the United States. Approximately 90 percent of
heavy alcohol drinkers develop fatty liver, resulting mainly from marked
abnormalities in hepatic lipid metabolism, specifically, from
accumulation of triacylglycerols and other lipids. In addition to
lipids accumulating in liver with chronic ethanol consumption, proteins
accumulate as well. Cytosolic proteins are largely responsible for this
increase and L-FABP which binds fatty acids and cholesterol accounted
for 22 percent of the total increase in liver cytosolic proteins in
chronic ethanol treated rats. Therefore, it is important to understand
how ethanol may directly act on L- FABP and SCP-2 with respect to
binding, displacement of endogenous ligands, and lipid transport.
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
555917996
UEI
KABJZBBJ4B54
Project Start Date
01-August-1996
Project End Date
31-January-2001
Budget Start Date
01-August-1998
Budget End Date
31-January-2001
Project Funding Information for 1998
Total Funding
$165,441
Direct Costs
$165,480
Indirect Costs
$43,025
Year
Funding IC
FY Total Cost by IC
1998
National Institute on Alcohol Abuse and Alcoholism
$165,441
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AA010806-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AA010806-03
Patents
No Patents information available for 5R01AA010806-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AA010806-03
Clinical Studies
No Clinical Studies information available for 5R01AA010806-03
News and More
Related News Releases
No news release information available for 5R01AA010806-03
History
No Historical information available for 5R01AA010806-03
Similar Projects
No Similar Projects information available for 5R01AA010806-03